XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 12,419,029 $ 15,748,480
Short-term investment securities 3,021,064 4,511,780
Interest receivable 28,894 94,375
Accounts receivable 528,151 277,831
Prepaid expenses and other current assets 244,170 375,830
Total current assets 16,241,308 21,008,296
Non-current assets:    
Long-term investment securities 1,998,120 0
Investment in Alphazyme 284,709 284,709
Other assets 6,104 6,117
Total assets 18,530,241 21,299,122
Current liabilities:    
Accounts payable 866,321 1,547,953
Accrued expenses 533,007 709,560
Deferred research and development obligations 315,006 151,147
Deferred license revenue, current portion 112,146 147,059
Total current liabilities 1,826,480 2,555,719
Deferred license revenue, net of current portion 308,823 352,941
Total liabilities 2,135,303 2,908,660
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding 0 0
Common stock, $.001 par value:Authorized shares - 100,000,000; issued shares - 40,332,659 and 39,747,659, outstanding shares - 28,079,157 and 27,494,157 as of June 30, 2021, and December 31, 2020, respectively 40,518 40,483
Additional paid-in capital 101,522,602 101,026,496
Treasury stock, shares held at cost - 12,253,502 (18,929,915) (18,929,915)
Accumulated deficit (66,238,267) (63,746,602)
Total stockholders’ equity 16,394,938 18,390,462
Total liabilities and stockholders’ equity $ 18,530,241 $ 21,299,122